BRIACELL THERAPEUTICS CORP (BCTX) Stock News

USA - Nasdaq - NASDAQ:BCTX - CA1079303071 - Common Stock

9.73 USD

-0.56 (-5.44%)

Last: 11/28/2025, 2:18:23 PM

10.07 USD

+0.34 (+3.49%)

After Hours: 11/28/2025, 2:18:23 PM

Technical Analysis

Fundamental Analysis

Analyst Ratings

Earnings Estimates

BCTX Latest News, Press Relases and Analysis

All

Press Releases

3 days ago - By: BriaCell Therapeutics Corp. - Mentions: BCT.CA

BriaCell to Highlight Positive Phase 2 & Phase 3 Clinical Data at SABCS® 2025

8 days ago - By: BriaCell Therapeutics Corp. - Mentions: BCT.CA

BriaCell and Receptor.AI to Collaborate on AI Driven Small Molecule Cancer Therapeutics

10 days ago - By: BriaCell Therapeutics Corp. - Mentions: BCT.CA

BriaCell Selected to Present Phase 2 & 3 Clinical Data at SABCS® 2025

21 days ago - By: BriaCell Therapeutics Corp. - Mentions: BCT.CA

BriaCell Presents Robust Anti-Cancer Activity of Bria-OTS+™ at SITC 2025

24 days ago - By: BriaCell Therapeutics Corp. - Mentions: BCT.CA

BriaCell to Present Robust Anti-Cancer Activity of Bria-OTS+™ in Breast and Prostate Cancer Models

a month ago - By: BriaCell Therapeutics Corp. - Mentions: BCT.CA

BriaCell Receives Positive Recommendation from Data Safety Monitoring Board (DSMB) for Phase 3 Study in Metastatic Breast Cancer

a month ago - By: BriaCell Therapeutics Corp. - Mentions: BCT.CA

BriaCell Adds Key Clinical Sites in Phase 3 Metastatic Breast Cancer Study

a month ago - By: BriaCell Therapeutics Corp. - Mentions: BCT.CA

BriaCell Announces Collaboration with MSK Accelerator to Advance Bria-OTS+™ for Breast Cancer

a month ago - By: BriaCell Therapeutics Corp. - Mentions: BCT.CA

BriaCell Presents Phase 3 Clinical Biomarker Data at ESMO 2025

2 months ago - By: BriaCell Therapeutics Corp. - Mentions: BCT.CA

BriaCell to Present Positive Clinical Biomarker Data of Phase 3 Study at ESMO 2025

2 months ago - By: BriaCell Therapeutics Corp. - Mentions: BCT.CA

BriaCell to Present Bria-OTS+™ Preclinical Data at SITC 2025 Annual Meeting

3 months ago - By: BriaCell Therapeutics Corp. - Mentions: BCT.CA

BriaCell’s Bria-OTS+™ Mechanism of Action Validated in Highly Rated Peer Reviewed Cancer Journal

3 months ago - By: BriaCell Therapeutics Corp. - Mentions: BCT.CA

BriaCell Awarded $2 Million NCI Grant to Advance Bria-PROS+™ in Prostate Cancer

3 months ago - By: BriaCell Therapeutics Corp. - Mentions: BCT.CA

BriaCell Announces Proposed Effective Date of Share Consolidation

4 months ago - By: BriaCell Therapeutics Corp. - Mentions: BCT.CA

BriaCell Selected for MSK’s 2025 Therapeutics Accelerator Program for Bria-OTS+™ for Cancer

4 months ago - By: BriaCell Therapeutics Corp. - Mentions: BCT.CA

BriaCell Announces Proposed Effective Date of Share Consolidation

4 months ago - By: BriaCell Therapeutics Corp. - Mentions: BCT.CA

BriaCell Adds UCLA Health as Key Site in Pivotal Phase 3 Breast Cancer Study

4 months ago - By: BriaCell Therapeutics Corp. - Mentions: BCT.CA

BriaCell Awarded New Zealand Patent for its Whole Cell Technology

4 months ago - By: BriaCell Therapeutics Corp.; BriaPro Therapeutics Corp. - Mentions: BCT.CA

BriaCell’s Subsidiary, BriaPro, Files Patent Application for Immuno-Oncology Platform with Novel Multitargeting Agents

4 months ago - By: BriaCell Therapeutics Corp. - Mentions: BCT.CA

BriaCell Announces Two Clinical Data Poster Presentations at ESMO 2025

5 months ago - By: BriaCell Therapeutics Corp. - Mentions: BCT.CA

BriaCell Therapeutics Announces Closing of $15 million Public Offering

5 months ago - By: BriaCell Therapeutics Corp. - Mentions: BCT.CA

BriaCell Therapeutics Announces Pricing of $15 million Public Offering

5 months ago - By: BriaCell Therapeutics Corp. - Mentions: BCT.CA

BriaCell Adds Mayo Clinic to Phase 3 Study in Metastatic Breast Cancer

5 months ago - By: BriaCell Therapeutics Corp. - Mentions: BCT.CA

BriaCell’s Bria-IMT™ Demonstrates Survival Advantage over Trodelvy® and Control Group in Metastatic Breast Cancer

5 months ago - By: BriaCell Therapeutics Corp. - Mentions: BCT.CA

BriaCell Reports Complete and Sustained Resolution of Brain Metastasis and Sustained Regression of Orbital Metastasis in “Eye-Bulging” Breast Cancer Patient

5 months ago - By: BriaCell Therapeutics Corp. - Mentions: BCT.CA

BriaCell Patient Achieves Sustained Complete Resolution of Lung Metastasis in Bria-OTS™ Metastatic Breast Cancer Study

5 months ago - By: BriaCell Therapeutics Corp. - Mentions: BCT.CA

BriaCell Phase 2 Survival Achievement: 52% of Patients Surpass One-Year Milestone in Metastatic Breast Cancer

5 months ago - By: BriaCell Therapeutics Corp. - Mentions: BCT.CA

BriaCell Highlights Additional Phase 3 Clinical Sites Including Los Angeles Cancer Network and Smilow Cancer Hospital at Yale New Haven

5 months ago - By: BriaCell Therapeutics Corp. - Mentions: BCT.CA

BriaCell Announces Positive Recommendation from Data Safety Monitoring Board for Pivotal Phase 3 Study in Metastatic Breast Cancer

6 months ago - By: BriaCell Therapeutics Corp. - Mentions: BCT.CA

BriaCell Announces Virtual Investor Presentations on Thursday, June 12 and Thursday, June 26

6 months ago - By: BriaCell Therapeutics Corp. - Mentions: BCT.CA

BriaCell Reports Robust Overall Survival and Clinical Benefit Data at ASCO 2025

6 months ago - By: BriaCell Therapeutics Corp. - Mentions: BCT.CA

BriaCell Bria-OTS™ Phase 1/2 Study Clears Safety Evaluation; Doses First Patient in Combination with Checkpoint Inhibitor

6 months ago - By: BriaCell Therapeutics Corp. - Mentions: BCT.CA

BriaCell Abstracts Showcase Positive Survival and Clinical Benefit Data at ASCO 2025

6 months ago - By: BriaCell Therapeutics Corp. - Mentions: BCT.CA

BriaCell CEO Letter to Shareholders